Future of clinical genomics in pediatric oncology.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-05-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2012.46.8470PMID 23589558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.

  2016cited by this paper
• Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas

  2012cited by this paper
• Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.

  2012cited by this paper
• Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.

  2012cited by this paper
• Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS

  2012cited by this paper
• Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

  2012cited by this paper
• A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion

  2012cited by this paper
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

  2012cited by this paper
• Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.

  2012cited by this paper
• A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors

  2012cited by this paper
• Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

  2012cited by this paper
• Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

  2012cited by this paper
• T‐cell acute lymphoblastic leukaemia: recent molecular biology findings

  2012cited by this paper
• Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma

  2012cited by this paper
• Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

  2012cited by this paper
• Reconstructing cancer genomes from paired-end sequencing data

  2012cited by this paper
• Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?

  2012cited by this paper
• Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy

  2012cited by this paper
• Neoplasms associated with germline and somatic NF1 gene mutations.

  2012cited by this paper
• Number of lymph nodes recovered as an independent prognostic factor in predicting outcome in patients with pathologically node-negative rectal cancer following preoperative chemo/radiotherapy.

  2012cited by this paper
• Dissecting the genomic complexity underlying medulloblastoma

  2012cited by this paper
• Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

  2012cited by this paper
• Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies

  2012cited by this paper
• Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

  2012cited by this paper
• Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

  2012cited by this paper
• A regression model for estimating DNA copy number applied to capture sequencing data

  2012cited by this paper
• The Pediatric Cancer Genome Project

  2012cited by this paper
• A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers.

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012cited by this paper
• High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes

  2012cited by this paper
• A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

  2012cited by this paper
• MAPK pathway activation in pilocytic astrocytoma

  2011cited by this paper
• Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

  2011cited by this paper
• Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure

  2011cited by this paper
• Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

  2011cited by this paper
• Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

  2011cited by this paper
• Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.

  2011cited by this paper
• Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV

  2011cited by this paper
• Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.

  2011cited by this paper
• Faculty Opinions recommendation of Increased methylation variation in epigenetic domains across cancer types.

  2011cited by this paper
• WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

  2011cited by this paper
• Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

  2011cited by this paper
• Increased methylation variation in epigenetic domains across cancer types

  2011cited by this paper
• Emerging importance of ALK in neuroblastoma.

  2011cited by this paper
• A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses

  2011cited by this paper
• SeqGene: a comprehensive software solution for mining exome- and transcriptome- sequencing data

  2011cited by this paper
• Molecular subgroups of medulloblastoma: the current consensus

  2011cited by this paper
• Genome analysis Advance Access publication April 2, 2012 CONTRA: copy number analysis for targeted resequencing

  2011cited by this paper
• Hybrid capture and next-generation sequencing identify viral integration sites from formalin-fixed, paraffin-embedded tissue.

  2011cited by this paper
• Genomic profiling of B-progenitor acute lymphoblastic leukemia.

  2011cited by this paper
• Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

  2011cited by this paper
• BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

  2011cited by this paper
• Abstract 4756: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation

  2011cited by this paper
• CREST maps somatic structural variation in cancer genomes with base-pair resolution

  2011cited by this paper
• Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

  2011cited by this paper
• IDH1 and IDH2 mutations in pediatric acute leukemia

  2011cited by this paper
• Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial.

  2011cited by this paper
• Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis

  2011cited by this paper
• Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

  2010cited by this paper
• Imatinib mesylate in children and adolescents with cancer

  2010cited by this paper
• Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

  2010cited by this paper
• Brain tumors: from childhood through adolescence into adulthood.

  2010cited by this paper
• Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.

  2010cited by this paper
• Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Recent advances in neuroblastoma.

  2010cited by this paper
• Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway

  2010cited by this paper
• Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

  2010cited by this paper
• Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network.

  2010cited by this paper
• Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.

  2010cited by this paper
• IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group

  2010cited by this paper
• Soft tissue tumors associated with EWSR1 translocation

  2010cited by this paper
• Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

  2010cited by this paper
• Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.

  2010cited by this paper
• A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25).

  2010cited by this paper
• A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.

  2010cited by this paper
• Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

  2010cited by this paper
• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

  2009cited by this paper
• Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

  2009cited by this paper
• Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

  2009cited by this paper
• Childhood acute lymphoblastic leukemia: update on prognostic factors

  2009cited by this paper
• Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.

  2009cited by this paper
• Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

  2009cited by this paper
• Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

  2009cited by this paper
• Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

  2009cited by this paper
• Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

  2009cited by this paper
• Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

  2009cited by this paper
• Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.

  2009cited by this paper
• International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

  2009cited by this paper
• Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

  2009cited by this paper
• A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

  2009cited by this paper
• BreakDancer: An algorithm for high resolution mapping of genomic structural variation

  2009cited by this paper
• Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing

  2008cited by this paper
• Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.

  2008cited by this paper
• Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.

  2008cited by this paper
• BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

  2008cited by this paper
• Oncogenic mutations of ALK kinase in neuroblastoma

  2008cited by this paper
• Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

  2008cited by this paper

• Fundamentals of Pediatric Cancer: How Pediatric Pathology and Infrastructure of Clinical Trials Impact Contemporary Interventional Oncology in Children

  2025cites this paper
• Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers

  2024cites this paper
• Diagnostic classification of childhood cancer using multiscale transcriptomics

  2023cites this paper
• Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants

  2022cites this paper
• „Liquid biopsies“ als neue Diagnostikplattform in der pädiatrischen Onkologie

  2021cites this paper
• Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?

  2021cites this paper
• Creating a cancer genomics curriculum for pediatric hematology‐oncology fellows: A national needs assessment

  2021cites this paper
• Circular RNAs in childhood‐related diseases and cancers: A review

  2020cites this paper
• Tumor Molecular Profiling: Pediatric Results of the ProfiLER Study.

  2020cites this paper
• Exploring Infant Leukemia through Exome Sequencing and an In Vitro Model of Hematopoietic Development

  2019cites this paper
• Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

  2019cites this paper
• The evidence for expanded genetic testing for pediatric patients with cancer.

  2018cites this paper
• Refined detection and phasing of structural aberrations in pediatric acute lymphoblastic leukemia by linked-read whole-genome sequencing

  2018cites this paper
• Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors.

  2018cites this paper
• Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology

  2018cites this paper
• Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors

  2017cites this paper
• Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

  2017cites this paper
• Precision medicine in pediatric oncology: Lessons learned and next steps

  2017cites this paper
• Precision medicine in pediatric oncology

  2017cites this paper
• Sharing Outside the Sandbox? The Child’s Right to an Open Data Sharing Future in Genomics and Personalized Medicine

  2017cites this paper
• An Update: Genetic Mutations and Childhood Cancers

  2017cites this paper
• Parental Perspectives on Whole Exome Sequencing in Pediatric Cancer: A Typology of Perceived Utility.

  2017cites this paper
• [The new challenge in oncology: Next-generation sequencing and its application in precision medicine].

  2016cites this paper
• Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina

  2016cites this paper
• Les inhibiteurs de BRAF et leurs applications potentielles en pédiatrie

  2016cites this paper
• Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma

  2016cites this paper
• Therapy-related myeloid neoplasms in children and adolescents

  2016cites this paper
• Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next steps

  2016cites this paper
• Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

  2016cites this paper
• Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

  2016cites this paper
• Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience

  2016cites this paper
• [The new challenge in oncology: Next-generation sequencing and its application in precision medicine].

  2016cites this paper
• Identifying therapeutic targets by elucidating signaling pathways in pediatric lymphoid leukemias

  2015cites this paper
• Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

  2015cites this paper
• The Progress and Challenges of Targeted Therapy for Pediatric Solid Tumors

  2015cites this paper
• Safety and diagnostic accuracy of tumor biopsies in children with cancer

  2015cites this paper
• State of the art discovery with tumor profiling in pediatric oncology.

  2015cites this paper
• Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

  2015cites this paper
• Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies

  2015cites this paper
• Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

  2015cites this paper
• Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma

  2013cites this paper
• Precision oncology: an overview.

  2013cites this paper